Literature DB >> 35678885

Brain infiltration of breast cancer stem cells is facilitated by paracrine signaling by inhibitor of differentiation 3 to nuclear respiratory factor 1.

Jayanta K Das1, Alok Deoraj1, Deodutta Roy1, Quentin Felty2.   

Abstract

Treatment options for brain metastatic breast cancer are limited because the molecular mechanism for how breast cancer cells infiltrate the brain is not fully understood. For breast tumors to metastasize to the brain first, cells need to detach from the primary tumor, enter in the blood circulation, survive within the microvascular niche, and then cross the blood-brain barrier (BBB) to colonize into the brain. It is critical to understand how breast cancer cells transmigrate through the BBB to prevent brain metastasis. Nuclear respiratory factor 1 (NRF1) transcription factor has been reported to be highly active in several human cancers and its aberrant expression facilitates in the acquisition of breast cancer stem cells (BCSCs). Inhibitor of differentiation protein 3 (ID3), a transcription regulating protein, induces pluripotent endothelial stem cells (ESCs). Herein, we investigated if NRF1-induced BCSCs could cross a BBB model and guiding of BCSCs by ID3-induced ESCs across the BBB. BCSCs and ESCs were subjected to functional gain/loss experiments to determine if NRF1/ID3 contributed to lineage-specific BCSCs organ entry. First, we tested whether NRF1 promoted migration of breast cancer using a BBB model consisting of BCSCs or MDA-MB231 cells, brain endothelial cell layer, and astrocytes. NRF1 overexpression increased the propensity for BCSCs and NRF1-induced MDA-MB231 cells to adhere to brain endothelial cells and migrate across a human BBB model. Increased adhesion of NRF1-induced BCSCs to ESCsID3 was detected. NRF1-induced BCSCs crossed through the BBB model and this was promoted by ESCsID3. We also showed that environmental relevant exposure to PCBs (PCB153 and PCB77) produced differential effects. Treatment with PCB153 showed increased growth of NRF1-induced BCSCs tumor spheroids and increased in vivo migration of ESCsID3. Exosomal ID3 released from endothelial cells also supported the growth of NRF1-induced BCSCs and provide the basis for paracrine effects by ESCsID3 associated with breast tumors. Xenograft experiments showed that ID3 overexpressing brain ESCs not only supported the growth of BCSC tumor spheroids but guided them to the neural crest in zebrafish. These findings show for the first time a novel role for ID3 and NRF1 by which ESCsID3 help guide BCSCsNRF1 to distant metastatic sites where they most likely facilitate the colonization, survival, and proliferation of BCSCs. This knowledge is important for pre-clinical testing of NRF1/ID3 modifying agents to prevent the spread of breast cancer to the brain.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Entities:  

Keywords:  Breast cancer metastasis; Cancer stem cells; ID3; NRF1

Mesh:

Substances:

Year:  2022        PMID: 35678885     DOI: 10.1007/s00432-022-04026-w

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  11 in total

1.  ID3 contributes to the acquisition of molecular stem cell-like signature in microvascular endothelial cells: its implication for understanding microvascular diseases.

Authors:  Jayanta K Das; Norbert F Voelkel; Quentin Felty
Journal:  Microvasc Res       Date:  2015-02-07       Impact factor: 3.514

2.  Estrogen-induced redox sensitive Id3 signaling controls the growth of vascular cells.

Authors:  Quentin Felty; Nicole Porther
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

3.  Microvascular lesions by estrogen-induced ID3: its implications in cerebral and cardiorenal vascular disease.

Authors:  Jayanta K Das; Quentin Felty
Journal:  J Mol Neurosci       Date:  2014-08-17       Impact factor: 3.444

4.  Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors.

Authors:  M Nishi; Y Sakai; H Akutsu; Y Nagashima; G Quinn; S Masui; H Kimura; K Perrem; A Umezawa; N Yamamoto; S W Lee; A Ryo
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

Review 5.  ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities.

Authors:  Radhika Nair; Wee Siang Teo; Vivek Mittal; Alexander Swarbrick
Journal:  Mol Ther       Date:  2014-05-14       Impact factor: 11.454

6.  Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer.

Authors:  Rakhi P Naik; David Jin; Ellen Chuang; Ellen G Gold; Eleni A Tousimis; Anne L Moore; Paul J Christos; Tatiana de Dalmas; Diana Donovan; Shahin Rafii; Linda T Vahdat
Journal:  Breast Cancer Res Treat       Date:  2007-02-15       Impact factor: 4.872

7.  In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness.

Authors:  Federica Brugnoli; Silvia Grassilli; Manuela Piazzi; Maria Palomba; Ervin Nika; Alberto Bavelloni; Silvano Capitani; Valeria Bertagnolo
Journal:  Mol Cancer       Date:  2013-12-13       Impact factor: 27.401

8.  The perivascular niche regulates breast tumour dormancy.

Authors:  Cyrus M Ghajar; Héctor Peinado; Hidetoshi Mori; Irina R Matei; Kimberley J Evason; Hélène Brazier; Dena Almeida; Antonius Koller; Katherine A Hajjar; Didier Y R Stainier; Emily I Chen; David Lyden; Mina J Bissell
Journal:  Nat Cell Biol       Date:  2013-06-02       Impact factor: 28.824

9.  Inhibitor of DNA binding 1 as a secreted angiogenic transcription factor in rheumatoid arthritis.

Authors:  Takeo Isozaki; M Asif Amin; Ali S Arbab; Alisa E Koch; Christine M Ha; Gautam Edhayan; G Kenneth Haines; Jeffrey H Ruth
Journal:  Arthritis Res Ther       Date:  2014-03-13       Impact factor: 5.156

10.  PCB153-induced overexpression of ID3 contributes to the development of microvascular lesions.

Authors:  Jayanta K Das; Quentin Felty
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.